Home Cart Sign in  
Chemical Structure| 51322-75-9 Chemical Structure| 51322-75-9

Structure of Tizanidine
CAS No.: 51322-75-9

Chemical Structure| 51322-75-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Tizanidine is an α2-adrenergic receptor agonist and inhibits neurotransmitter release from CNS noradrenergic neurons.

Synonyms: Tizanidine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Phelelisiwe S. Dube ; Dylan Hart ; Lesetja J. Legoabe ; Audrey Jordaan ; Digby F. Warner ; Richard M. Beteck

Abstract: Nitrothiazole derivatives have been reported to exhibit activity against aerobic, anaerobic, and microaerophilic bacteria. This activity profile makes the nitrothiazole compound class an ideal lead source against Mycobacterium tuberculosis, which flourishes in varied environments with different oxygen concentrations. In this work, we investigated six nitrothiazole derivatives for antitubercular activity. The compounds exhibited potent activity, with compounds 9 and 10 possessing an equipotent MIC90 value of 0.24 µM. The compounds were investigated for cytotoxicity against HEK293 cells and hemolysis against red blood cells, and they demonstrated no cytotoxicity nor hemolytic effects, suggesting they possess inherent antitubercular activity.

Keywords: nitrothiazole ; Mannich bases ; antitubercular activity ; tuberculosis ; Mycobacterium tuberculosis

Purchased from AmBeed: ; ;

Alternative Products

Product Details of Tizanidine

CAS No. :51322-75-9
Formula : C9H8ClN5S
M.W : 253.71
SMILES Code : ClC1=C(NC2=NCCN2)C3=NSN=C3C=C1
Synonyms :
Tizanidine
MDL No. :MFCD00865192

Safety of Tizanidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H361
Precautionary Statements:P201-P202-P264-P270-P280-P301+P312+P330-P308+P313-P220-P405-P501

Related Pathways of Tizanidine

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02403687 - Completed - -
NCT01753882 Spinal Cord Injury Phase 1 Unknown July 2017 United States, Illinois ... More >> Rehabilitation Institute of Chicago Chicago, Illinois, United States, 60611 Less <<
NCT01547234 - Completed - Israel ... More >> Multiple Sclerosis Center Carmel Medical Center Haifa, Israel Less <<
NCT02853240 Cerebral Palsy Not Applicable Recruiting April 2020 France ... More >> Hôpital Femme Mère Enfant Recruiting Bron, France, 69500 Contact: Claire MIETTON, MD    (0)4 72 12 95 04 ext +33    claire.mietton@chu-lyon.fr    Contact: Tiphanie GINHOUX, CRA    (0)4 72 35 72 31 ext +33    tiphanie.ginhoux@chu-lyon.fr Less <<
NCT01788969 Spinal Cord Injury Phase 1 Unknown December 2017 United States, Illinois ... More >> Rehabilitation Institute of Chicago Chicago, Illinois, United States, 60611 Less <<
NCT01244113 Cerebral Palsy Not Applicable Completed - Korea, Republic of ... More >> Severance Hospital Seoul, Korea, Republic of, 120-752 Less <<
NCT02508805 Vertebrogenic Radiculopathy L5... More >>, S1 Less << Phase 3 Completed - Russian Federation ... More >> State Autonomous Institution Republican Clinical Centre of Neurology Kazan, Republic of Tatarstan, Russian Federation, 420021 Less <<
NCT02887534 Acute Muscle Pain Phase 2 Withdrawn December 2017 -
NCT03068897 Low Back Pain Phase 4 Completed - United States, New York ... More >> Montefiore Medical Center Bronx, New York, United States, 10467 Less <<
NCT02907775 Muscle Spasticity ... More >> Stroke Less << Not Applicable Recruiting November 30, 2018 United Kingdom ... More >> Sheffield Teaching Hospitals NHS FT Recruiting Sheffield, United Kingdom Contact: Alisha Patel       alisha.patel@sth.nhs.uk Less <<
NCT01068847 Drug Dependence Phase 1 Completed - United States, Arkansas ... More >> University of Arkansas for Medical Sciences Little Rock, Arkansas, United States, 72205 Less <<
NCT00430196 Upper Limb Spasticity Phase 4 Completed - -
NCT00047580 Multiple Sclerosis ... More >> Muscle Spasticity Spinal Cord Injury Stroke Less << Phase 3 Completed - United States, Arizona ... More >> Radiant Research Tucson, Arizona, United States, 85710 United States, California The Neurology Center Encinitas, California, United States, 92024 Northridge Neurological Center Northridge, California, United States, 91325 The Neurology Center Oceanside, California, United States, 92056 Neurology Medical Group of Diablo Valley Walnut Creek, California, United States, 94598 United States, Colorado Colorado Neurology Movement Disorders Center Englewood, Colorado, United States, 80110 United States, Connecticut Yale Center for MS Treatment and Research New Haven, Connecticut, United States, 06510 United States, Florida Neurology Clinic Research Institution Plantation, Florida, United States, 33324 Axiom Clinical Research Tampa, Florida, United States, 33609 United States, Georgia Comprehensive Neurology Specialists, PC Atlanta, Georgia, United States, 30338 Neurotrials Research, Inc. Atlanta, Georgia, United States, 30342 United States, Illinois Springfield Clinic Neuroscience Institute Springfield, Illinois, United States, 62702 United States, Minnesota The Minneapolis Clinic of Neurology, Ltd. Minneapolis, Minnesota, United States, 55422 United States, Oklahoma Neurological Associates of Tulsa, Inc. Tulsa, Oklahoma, United States, 74136-8327 United States, Oregon Medford Neurological and Spine Clinic Medford, Oregon, United States, 97504-8456 United States, Rhode Island Sargent Rehabilitation Center Warwick, Rhode Island, United States, 02818 Less <<
NCT01979510 Low Back Pain Phase 3 Withdrawn May 2014 -
NCT00287157 Traumatic Brain Injury Phase 1 Completed - Israel ... More >> Alyn Hospital Pediatric and Adolescent Rehabilitation Center Jerusalem, Israel, 01090 Less <<
NCT02934061 Low Back Pain Phase 3 Completed - Romania ... More >> Opera Contract Research Organization SRL Timisoara, Timis, Romania, 300209 Less <<
NCT00464958 Spasticity Mu... More >>ltiple Sclerosis Less << Phase 1 Phase 2 Terminated(Study was stopped a... More >>s the sponsor is no longer funding this project) Less << - Israel ... More >> Tel Aviv Sourasky Medical Center Tel Aviv, Israel, 64239 Less <<
NCT02725359 Thyroidectomy Phase 4 Completed - Turkey ... More >> Ataturk University Yakutiye, Erzurum, Turkey, 25100 Less <<
NCT01839279 Spasticity Phase 2 Completed - United States, Texas ... More >> Covance- Dallas Dallas, Texas, United States, 75247 Less <<
NCT01844674 Malignant Melanoma, Neoplasms Phase 1 Completed - United States, California ... More >> Diablo Valley Oncology and Hematology Pleasant Hill, California, United States, 94523 United States, Michigan Karmanos Cancer Center Detroit, Michigan, United States, 48201 United States, North Carolina Duke University Health Systems Durham, North Carolina, United States, 27710 Brazil Instituto Nacional do Cancer - INCA Rio de Janeiro, RJ, Brazil, 20560-120 Hospital de Caridade de Ijui; Oncologia Ijui, RS, Brazil, 98700-000 CITO - Centro Integrado de Terapia Onco-Hematológica - Hospital da Cidade de Passo Fundo Passo Fundo, RS, Brazil, 99010-260 Hospital Sao Lucas - PUCRS Porto Alegre, RS, Brazil, 90610-000 Canada, Quebec CSSS champlain - Charles-Le Moyne Greenfield Park, Quebec, Canada, J4V 2H1 Cyprus Bank of Cyprus Oncology Center Nicosia, Cyprus, 2006 Korea, Republic of Severance Hospital, Yonsei University Health System Seoul, Korea, Republic of, 03722 Samsung Medical Center Seoul, Korea, Republic of, 06351 Asan Medical Center. Seoul, Korea, Republic of, 138-736 Less <<
NCT01405950 Spasticity Due to Cerebral Pal... More >>sy Less << Phase 1 Terminated(Please see 'Further... More >> study details as provided by Acorda Therapeutics' for explanation of why study stopped.) Less << - United States, Kentucky ... More >> University of Louisville Department of Neurology dba Kentucky Neuroscience Research Health Care Outpatient Center (HCOC) Louisville, Kentucky, United States, 40202 Less <<
NCT01146028 Healthy PHASE1 COMPLETED 2025-11-01 Anapharm Inc., Sainte-Foy (Que... More >>bec), Canada Less <<
NCT00358293 Muscle Spasticity Phase 1 Phase 2 Completed - Israel ... More >> Tel Aviv Sourasky Medical Center- Neurology Department Tel Aviv, Israel Less <<
NCT01839279 - Completed - -
NCT02016443 Unilateral Inguinal Hernia Phase 4 Completed - Turkey ... More >> Diskapi Yildirim Beyazit training and research hospital Ankara, Turkey Less <<
NCT01405950 - Terminated(Please see 'Further... More >> study details as provided by Acorda Therapeutics' for explanation of why study stopped.) Less << - -
NCT01065987 Healthy PHASE1 COMPLETED 2025-11-01 Anapharm Inc., Sainte-Foy (Que... More >>bec), Canada Less <<
NCT06258785 Postoperative Urinary Retentio... More >>n|Sacrospinous Vaginal Vault Suspension|Reconstructive Pelvic Surgery Less << PHASE3 RECRUITING 2025-04-01 NorthShore University Health S... More >>ystem, Skokie, Illinois, 60076, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.94mL

0.79mL

0.39mL

19.71mL

3.94mL

1.97mL

39.42mL

7.88mL

3.94mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories